---
schema_version: "secwatch.filing_event.v1"
accession: "0001453687-25-000059"
form_type: "8-K"
ticker: "RNAC"
cik: "0001453687"
company_name: "Cartesian Therapeutics, Inc."
filed_at: "2025-03-13T23:59:59+00:00"
generated_at: "2026-05-24T20:54:48.690078+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Cartesian Therapeutics FY2024 net loss $77.4M; cash $214.3M; Phase 3 MG trial on track

## Summary
- Net loss of $77.4M ($4.48 loss per share) vs $219.7M loss in FY2023; R&D expenses $45.1M.
- Cash, equivalents and restricted cash $214.3M at Dec 31, 2024; expected to fund operations into mid-2027.
- Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track for 1H25; FDA SPA agreement secured.
- Preliminary Phase 2 SLE data expected 2H25; Phase 2 pediatric basket trial to initiate 2H25 in select autoimmune indications.
- Dosing ongoing in first-in-human Phase 1 trial of Descartes-15 for multiple myeloma.

## SEC filing metadata
- accession: 0001453687-25-000059
- form_type: 8-K
- ticker: RNAC
- cik: 0001453687
- company_name: Cartesian Therapeutics, Inc.
- filed_at: 2025-03-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453687/000145368725000059/0001453687-25-000059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453687/000145368725000059/rnac-20250313.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001453687-25-000059
- JSON: https://secwatch.observer/filing/0001453687-25-000059.json
- Plain text: https://secwatch.observer/filing/0001453687-25-000059.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.